Zoetis Inc. (NYSE:ZTS) Holdings Reduced by Brasada Capital Management LP

Brasada Capital Management LP lowered its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 83.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,035 shares of the company's stock after selling 31,369 shares during the quarter. Brasada Capital Management LP's holdings in Zoetis were worth $1,004,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in ZTS. Vanguard Group Inc. raised its stake in Zoetis by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after acquiring an additional 120,158 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Zoetis by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company's stock worth $1,726,075,000 after purchasing an additional 190,137 shares during the period. Polen Capital Management LLC lifted its holdings in Zoetis by 17.5% in the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock worth $1,219,237,000 after purchasing an additional 1,116,541 shares during the period. Wellington Management Group LLP increased its stake in Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after buying an additional 3,059,255 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Zoetis by 8.5% during the 4th quarter. Bank of New York Mellon Corp now owns 5,561,910 shares of the company's stock valued at $906,202,000 after buying an additional 433,429 shares during the period. Institutional investors own 92.80% of the company's stock.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several recent analyst reports. Morgan Stanley decreased their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Stifel Nicolaus lowered their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Barclays raised their target price on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, Piper Sandler boosted their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $214.40.

Zoetis Trading Up 2.3 %

Zoetis stock opened at $150.17 on Wednesday. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The firm has a market capitalization of $67.00 billion, a price-to-earnings ratio of 27.45, a P/E/G ratio of 2.78 and a beta of 0.92. The company has a 50 day moving average price of $159.19 and a 200 day moving average price of $169.22.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.33%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's payout ratio is presently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.